Alzamend Neuro Stock Forum

$Alzamend Neuro (ALZN.US)$
Can This New Lithium Formulation Revolutionize Bipolar Disorder Treatment? Alzamend's Phase II Trial Targets 7M+ Patients

$Alzamend Neuro (ALZN.US)$
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
Tuesday, 4th March at 8:10 am
ATLANTA, March 04, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorde...

$Alzamend Neuro (ALZN.US)$
Can Alzamend's New Lithium Formulation Eliminate Monitoring Requirements? Phase II Trial Set for 2025

$Alzamend Neuro (ALZN.US)$
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025
Benzinga· 1 min ago
Alzamend Neuro(ALZN.US)
On Tuesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced its plans to initiate the first of five phase 2 clinical studies of AL001. The first study, in healthy human subjects, is expected to commence in the second quarter of 2025.
The study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical...

$Alzamend Neuro (ALZN.US)$ Trash

$Alzamend Neuro (ALZN.US)$ EXCLUSIVE: Alzamend Tells Benzinga 'Head-to-head Studies of AL001 Versus a Marketed Lithium Carbonate Product Will Be Conducted for Comparisons of Lithium Blood and Brain/brain-structure Pharmacokinetics in Healthy, Alzheimer's Disease, BD, MDD, and PTSD'
Benzinga· 1 min ago
On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced it had completed the head coil by Tesla Dynamic Coils BV.
The development of the head coil was necessary to facilitate Alzamend's fiv...

$Alzamend Neuro (ALZN.US)$
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Thursday, 12th December at 8:00 am
• During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million
• Stockholder equity of $3.8 million at October 31, 2024, including $4.1 million of cash
• Strengthened balance sheet in preparation for five clinical trials to be initiated in 2025
Alzamend Neuro, Inc. (NASDAQ: ALZN) ("...

$Alzamend Neuro (ALZN.US)$ this grabge should move its horrible

$Alzamend Neuro (ALZN.US)$ Alzamend Neuro Tells Benzinga 'Data Confirm the Positive Topline Results Announced in June 2023 Identifying a Maximum Tolerated Dose as Assessed by an Independent Safety Review Committee'!
Alzamend Neuro Tells Benzinga 'Identified Dose Is Unlikely to Require Lithium Therapeutic Drug Monitoring'

$Alzamend Neuro (ALZN.US)$ EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's
Benzinga· just
On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary results were released in June 2023.
Identified by an independent safety review committee, this MTD represents a pivotal ...